Picture biomindz Mainz Biomed LSE Colorectal Cancer Screening 650x100px

Person › Details

Rodger Novak (CRISPR Therapeutics AG (Nasdaq: CRSP))

Novak, Rodger (CRISPR Therapeutics 201712– Board Chairman 2013–201711 CEO + Co-Founder before Sanofi + Nabriva GmbH)

	Organisation	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Former/major organisation	SR One Capital Management
	Group	SR One (Group)
	Product	CRISPR gene editing technology
	Product 2	anti-infective drug

Record changed: 2024-07-31

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x200px

More documents for Rodger Novak

[1] AIRNA Corporation. (9/19/23). "Press Release: AIRNA Launches to Develop New Class of RNA Editing Therapeutics for Rare and Common Diseases". Cambridge, MA & Tübingen....
[2] CRISPR Therapeutics AG. (3/29/23). "Press Release: CRISPR Therapeutics Announces Departure of Board Member". Zug & Boston, MA....
[3] SR One Capital Management. (11/19/20). "Press Release: SR One Completes Spin-out from GSK and Closes First Fund at $500 Million". San Francisco, CA & London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]